Business
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, June 18, 2019\n\n\n\n-Disease control rate of up to 83% achieved; evidence of improved survival for patients\n TORONTO and HOUSTON, June 18, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered Cytokines, will present today preliminary top-line clinical results from their Phase 2b trial of MDNA55, an IL4-guided toxin, in patients with recurrent Glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer, at the Inaugural Immuno-Oncology Pharma Congress held from June 18-20, 2019 during World Pharma Week in Boston, MA.\nThe presentation by Dr. Fahar Merchant, Chairman, President & CEO of Medicenna, will focus on safety and preliminary efficacy results from the Phase 2b clinical trial MDNA55-05, which recently completed its enrollment (N=46). \n\"The preliminary top-line clinical results of the Phase 2b trial of MDNA55 are very promising when compared to approved therapies for rGBM especially in patients exhibiting high levels of IL4R expression, a biomarker for more aggressive forms of brain cancer,\" said Dr. Fahar Merchant. \"While treatment options for patients with rGBM are very limited, MDNA55 has shown early evidence of substantial clinical benefit as well as improved survival for patients. We believe these results are evidence of the opportunity for MDNA55 to become a leading treatment option for a sizeable patient population with this devastating disease.\"\nHighlights from the presentation included:\nDisease control rate of up to 83% overall achievedTo account for initial local inflammation (called pseudo-progression) that can occur up to six months after treatment with MDNA55 in some subjects (and which can mask underlying tumor response), assessment of...